Here is a dream: find and destroy every tumorous cell in the body, especially those that get into the blood and mercilessly rove for other sites to inhabit. Some scientists in the field of circulating tumor cell (CTC) 3 research feel we are closer to realizing this dream than ever before.
The first CTC was identified in 1869. Dr. Peter Kuhn, a professor of biology at the University of Southern California, shared with Clinical Chemistry 3 major advances that provide the foundation for his contributions to the field.
To begin with, the work behind the first US Food and Drug Administration-approved diagnostic test for CTCs, CellSearch®, demonstrated that it was possible to find CTCs and also showed that their volume was related to the evolution of disease. Next, during the time he was at the Scripps Research Institute, along with colleagues such as pathologist Dr. Kelly Bethel, Kuhn showed that cells found in the circulatory system resemble those in the primary tumor from an anatomical pathology point of view (1 ) . Finally, Mehmet Toner, professor of surgery at the Massachusetts General Hospital, and colleagues established that when changes in the circulatory system were monitored, one could detect the emergence of drug resistance. Which brings us to today, and Dr. Kuhn's latest work.
What Is the Innovation?
Kuhn uses the phrase "no cell left behind" when describing his approach toward CTC detection and characterization. The breakthrough in his system is the ability to maintain all cells, without enriching the samples with particular tumor markers, and still be able to pull out significant CTC signals. The logic is that with no enrichment, there is no bias in sampling toward those cells that express the markers. And of practical value to a diagnostic pathologist, the cells are delivered on slides (not just counted) and can be further introduced into a standard laboratory work flow.
How does it work?
The system begins with a peripheral blood sample that is processed within 24 h (Fig. 1) . The red blood cells are lysed and the nucleated cells applied onto proprietary glass slides of the same size used in everyday microscopy. In a typical assay, the slides are stained with fluorescent antibodies to cytokeratin and CD45 and, for identification of DNA, 4Ј,6-diamidino-2-phenylindole (DAPI).
The slides are then scanned by a fluorescent scanning microscope at 10ϫ in 3 colors to capture thousands of images per slide. Computational algorithms then analyze the images to pick out candidate CTCs that are cytokeratin positive, CD45 negative, and have other morphological qualities (2 ) . Once identified, technical analysts annotate the results to provide specific improvements to the algorithms and create lists of candidate cells for further interpretation by a pathologist. The identified CTCs are further imaged at a 40ϫ resolution to pull out detailed morphological characteristics (Fig.  1) . If further genomic analysis is desired, single cells can be extracted. To facilitate feedback, the entire process is online. Kuhn's inspiration to design this platform has been to answer questions about cancer cells such as, "why do they survive?" and "what is their own biology?" "This is an incredibly robust way of identifying cancer cells," Kuhn says. "We simply modify the antibodies if we want to expand our reach, or we search by different morphological parameters if we want to look by shapes."
An early collaboration with Microsoft Corporation provided the direction to deal with vast amounts of data on which pathologists can view and annotate CTCs. Kuhn has a number of collaborators, but says massive collaboration upon a shared dataset is a "surprisingly hard problem" that requires that sample preparation, imaging, and analysis are all in sync with one another.
Where Can This Technology Fit?
"Through new technology we can see new things in blood that we couldn't see before," says Evi Lianidou, Professor of Analytical Chemistry at the University of Athens. "Now you can apply the fantastic tumor biology in this area." "The evidence screaming for the potential of circulating biomarkers, especially in the field of CTCs, is accumulating through many studies during the last years," said Lianidou.
In a recent report, Kuhn and colleagues applied their platform to study the therapeutic pressure in prostate cancer (3 ). They sampled the blood of a patient with prostate cancer and bone metastasis over 4 time points. Sample 1 was collected at baseline, before chemotherapy was given. Sample 2 was collected after chemotherapy, external-beam radiotherapy, and a bone-targeting radiopharmaceutical. Sample 3 was collected after 3 weeks of treatment Morphometric parameter-driven assay analysis identifies candidate cells for further characterization. Identified candidates can be characterized through high-resolution morphometry, protein content, protein subcellular localization, and single-cell next generation sequencing. CTM, circulating tumor microemboli; AR, androgen receptor; CK, cytokeratin. ©Reproduced with permission from Peter Kuhn.
with a highly selective androgen synthesis inhibitor. Sample 4 was collected at 9 weeks of treatment with the selective androgen synthesis inhibitor.
At the time of collection of sample 3 the patient was showing a clinical improvement, with less pain and lower prostate-specific antigen (PSA) concentrations. However, a single resistant clone had emerged, and by sample 4 this resistant clone dominated the picture, accompanied by increased pain and PSA values. The patient died soon after.
"At 3 weeks we could have known resistance was emerging," says Kuhn. "If we do therapy right, we can manipulate disease, but we need to constantly stay on top of it."
Kuhn believes success in the future will come from the convergence across scientific approaches. "We will get to a point when we start thinking of spatial and temporal resolution of disease in a patient," he says. "Bringing everyone together, we all need to describe the disease in order to make progress."
He acknowledges this convergence will bring into play biomarkers other than CTCs. In recent work by Dana Tsui and colleagues of Cambridge University [Dawson et al. (4 ) ], circulating tumor DNA was able to show tumor response earlier than a computed tomographic scan in patients with metastatic breast cancer.
In regard to the work by Tsui and colleagues, Lianidou says, "Prospective clinical studies that are evaluating its clinical significance are now underway, and based on the results shown in publications up to now I hope that they will be very promising." So when will it be game over for Waldo? "Important challenges for all circulating biomarker developments are assay sensitivity, specificity, standardization, and validation," says Lianidou. "These steps are absolutely necessary before their implementation in clinical practice." 
